A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors

Summary

This study aims to evaluate the safety and tolerability of HRS-7058 combined with antitumor drugs in subjects with solid tumors, and to determine the recommended dosage for Phase II. Evaluate the objective response rate of HRS-7058 in combination with anti-tumor drugs in subjects with solid tumors.

Timeline

Start

2025-07-09

Primary completion

2027-06

Completion

2027-07

Drugs

Indications